Cocooning: Influenza Vaccine for Parents and Caregivers in an Urban, Pediatric Medical Home.
Adult; Female; Male; Aged; Child; Infant; Caregivers; Parents; Nurse Practitioners; Human; Chi Square Test; Funding Source; Middle Age; Fisher's Exact Test; Adolescence; Pearson's Correlation Coefficient; Preschool; McNemar's Test; Pediatricians; Wilcoxon Rank Sum Test; Influenza – Prevention and Control – In Infancy and Childhood; Influenza – Risk Factors; Influenza Vaccine – Administration and Dosage
White PC; Baum DL; Ross H; Falletta L; Reed MD
Clinical pediatrics
2010
2010
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1177/0009922810374353" target="_blank" rel="noreferrer noopener">10.1177/0009922810374353</a>
From mechanisms to management: translating the neuropathic pain consensus recommendations into clinical practice.
Adult; Female; Humans; Middle Aged; Aged; Chronic Disease; Inflammation; Risk Factors; Evidence-Based Medicine; Practice Guidelines as Topic; Patient Selection; Acute Disease; Analgesics/therapeutic use; Patient Education as Topic; *Pain/diagnosis/etiology/physiopathology; Anticonvulsants/therapeutic use; Nervous System Diseases/*complications; Nurse Practitioners; Pain Management; Anesthetics; Drug Therapy; Combination; Antidepressive Agents; Local/therapeutic use; Tricyclic/therapeutic use
Chronic neuropathic pain poses a treatment challenge, and is associated with significant psychologic distress, physical disability, and impaired functioning, which impact the activities of daily living. Efforts to provide relief are often inadequate and/or require polypharmacy. This has spurred interest among researchers and clinicians alike to develop early, intensive treatments that target the molecular and cellular mechanisms involved in pain transduction, transmission, and modulation, or ideally, that prevent neuropathic pain from occurring in the first place. Currently, researchers are attempting to capitalize on our understanding of neuropathic pain pathophysiology to develop drugs that interrupt distinct activities involved in its perpetuation. In this regard, several potential agents (eg, NMDA and AMPA/kainate antagonists) are in phase 2 and 3 clinical trials. In the interim, evolving data and evidence-based neuropathic treatment recommendations provide guidance for selecting first- and second-line medications that alone or in combination offer acceptable neuropathic pain control and allow clinicians to bridge the gap between current knowledge and its application in the clinical setting. Hopefully, as basic and clinical science progresses, further treatment advances and management tools will be found to improve the care of patients who live with neuropathic pain.
Chevlen Eric; Davis Pamela Stitzlein; Rhiner Michelle
Journal of the American Academy of Nurse Practitioners
2005
2005-06
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).